Filing Analysis
MacroGenics, Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders approved the election of Class I directors, ratified the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2026, approved executive compensation on an advisory basis, and approved an amendment to the 2023 Equity Incentive Plan.
📋 Key Facts
- The Annual Meeting was held on May 19, 2026, with approximately 58% of outstanding shares represented (36,744,013 shares out of 63,560,068).
- Class I directors Scott Koenig, M.D., Ph.D., Federica O'Brien, and Eric Risser were elected.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026 with 36,689,683 votes 'For'.
- An amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan was approved to increase the number of shares of common stock available for issuance by 1,250,000 shares.
MacroGenics, Inc. announced its financial and operating results for the first quarter ended March 31, 2026. The disclosure was made via a press release attached as Exhibit 99.1 to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed on May 13, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
MacroGenics announced the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash. The transaction includes a long-term manufacturing and supply agreement ensuring MacroGenics retains access to clinical production services.
📋 Key Facts
- MacroGenics to receive $122.5 million in cash at closing, subject to customary adjustments.
- Potential for an additional $5 million in post-closing payments based on milestones and services through 2028.
- Assets being sold include the manufacturing facility in Rockville, Maryland, and warehouse operations in Frederick, Maryland.
- MacroGenics will enter into a manufacturing and supply agreement with the purchaser to secure future clinical supply.
- The transaction is expected to close in the third quarter of 2026.
MacroGenics amended its royalty purchase agreement with Sagard Healthcare Partners, securing an additional $60 million cash payment in exchange for royalty rights to ZYNYZ (retifanlimab-dlwr). This brings the total aggregate purchase price to $130 million, with a revised repayment cap and a potential $20 million milestone based on 2026 sales performance.
📋 Key Facts
- Received an additional $60.0 million cash payment from Sagard on May 1, 2026.
- Total aggregate purchase price for ZYNYZ royalties increased from $70 million to $130 million.
- Royalty rights revert to MacroGenics once Sagard receives 1.70x of the aggregate price by September 30, 2032, or 2.0x thereafter.
- Eligible for a one-time milestone payment of up to $20.0 million based on ZYNYZ achieving specific 2026 net sales thresholds.
- MacroGenics retains other economic interests including future development, regulatory, and commercial milestones under its original agreement with Incyte Corporation.
MacroGenics announced that the U.S. FDA has removed the partial clinical hold on its Phase 2 LINNET study of lorigerlimab. This allows the company to resume full clinical development of the bispecific DART molecule for patients with gynecologic cancers.
📋 Key Facts
- The FDA removed the partial clinical hold on April 8, 2026.
- The affected study is the Phase 2 LINNET trial.
- Lorigerlimab is an investigational bispecific DART molecule targeting PD-1 and CTLA-4.
- The study focuses on patients with gynecologic cancers.
MacroGenics, Inc. announced its financial and operating results for the fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial and operating results for the year ended December 31, 2025.
- The announcement was made on March 9, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A full press release is attached as Exhibit 99.1.
MacroGenics, Inc. announced that Class I director Jay Siegel, M.D. will not stand for re-election at the company's 2026 Annual Meeting of Stockholders. The departure is for personal reasons and does not involve any disagreements with the company.
📋 Key Facts
- Jay Siegel, M.D. notified the Board of Directors on February 25, 2026, that he will not seek re-election.
- Dr. Siegel is a Class I director.
- The decision was cited as being for personal reasons.
- The company stated there were no disagreements regarding operations, policies, or practices.
MacroGenics announced that the FDA has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in patients with gynecologic cancers.
🚩 Red Flags
- FDA partial clinical hold indicates potential safety concerns or regulatory deficiencies.
- Significant risk to clinical development timelines for a key pipeline asset.
📋 Key Facts
- The FDA issued a partial clinical hold on February 23, 2026.
- The affected study is the Phase 2 LINNET trial evaluating lorigerlimab.
- Lorigerlimab is an investigational bispecific DART molecule targeting PD-1 and CTLA-4.
- The study targets patients with gynecologic cancers.